FDA’s rating of Syntex' Synarel
When Synarel (transnasal nafarelin) was approved in February for treating endometriosis, FDA gave the drug a "1B" rating denoting a new chemical entity representing a modest therapeutic gain over existing therapies ("The Pink Sheet" Feb. 19, p. 3). However, as indicated in FDA's list of February approvals, the agency changed Synarel's rating to "1 C" or a new chemical entity offering little or no therapeutic gain ("The Pink Sheet" April 16, p. 11). According to FDA, the agency decided to change the rating because it was determined that Synarel has a side effect profile similar to an already approved endometriosis treatment, Sterling's danazol (Danocrine). FDA had originally thought that Synarel's side effect profile was better than danazol's.
You may also be interested in...
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.